Hims & Hers Health, Inc.

HIMS · SEC

Hims is using GLP-1 weight loss to expand the platform, but the quality test is retention and cash flow.

Consumer Health Convertible Notes Coverage Bootstrap Deep Dive Earnings Recap GLP-1

Latest ReportJun 5, 2026Hims and Hers Health: Decoding The Business Model Pivot Toward GLP-1 Weight LossView report ->Total Reports6Published reportsView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->

Company filters1 of 6 reports match

Clear filters

Add tags

Selected tags

Convertible Notes

Clear tags

Latest Thesis

HIMS this week: Canada GLP-1 expansion meets a $402.5M convert test

Hims & Hers opened a Canada generic semaglutide path and closed $402.5M of zero-coupon convertible debt. The update turns HIMS into a global expansion versus dilution proof test.

May 22, 2026Research reportSlides available

Read report Open slides Discussion (0)

Hims & Hers Health, Inc.this week: Canada GLP-1 expansion meets a $402.5M convert testMay 22, 2026

Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.

Recent Reports

Compact report index for this company.

View all 1 reports ->